Clinical Update: Colon, Rectal, and Anal Cancers

Seminars in Oncology Nursing

Volumn 28, Issue 4, 2012, Pages

  Wilkes, Gail ^a   Hartshorn, Kevan ^b  

^a Boston Medical Center ^*

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Anal cancer; Colon cancer; Colorectal cancer; Rectal cancer

Indexed keywords

ANUS TUMOR; ARTICLE; COLON TUMOR; HUMAN; PATHOLOGY; RECTUM TUMOR;

ANUS NEOPLASMS; COLONIC NEOPLASMS; HUMANS; RECTAL NEOPLASMS;

EID: 84868126755     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.09.012     Document Type: Article

References (132)

1. Siegel R., Naishadham D., Jemal A., et al. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Khattak M.A., Martin H.L., Beeke C., et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: Results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 2012, (Epub ahead of print, PMID 22763194).
3. Pawlik T.M., Schulick R.D., Choti M.A. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008, 13:51-56.
4. Headrick J.R., Miller D.L., Nagorney D.M., et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001, 71:975-980.
5. Edwards B.K., Ward E., Kohler B.A., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
6. American Cancer Society. Colorectal cancer facts and figures, 2011-2013. Atlanta, GA; American Cancer Society. Available at: (accessed August 5, 2012). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf.
7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK. editors. SEER cancer statistics review, 1975-2008. Bethesda, MD; National Cancer Institute. Available at: Based on November 2010 SEER data submission (accessed March 21, 2012). http://seer.cancer.gov/csr/1975_2008/.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. Colon and rectal cancer. In: American Joint Committee on Cancer (AJCC) Staging Manual. Ed 7. New York: Springer; 2010: pp. 143-163.
9. Wei E.K., Giovannucci E., Wu K., et al. Comparison of risk factors for colon and rectal cancer. Intl J Cancer 2003, 108:433-442.
10. Colditz G.A., Atwood K.A., Emmons K., et al. Harvard report on cancer prevention. Vol 4. Harvard Cancer Risk Index. Cancer Causes Control 2000, 11:477-488.
11. Luchtenborg M., Weijenberg M.P., Kampman E., et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol 2005, 161:806-815.
12. Libutti SK, Saltz LB, Tepper JE. Colon cancer. In: De Vita VT, Lawrence TS, Rosenberg SA, editors. Ed 8. Cancer Principles and Practice. Philadelphia, PA; Lippincott Williams & Wilkins: pp. 1232-1285.
13. Griffin-Sobel J.P. Characteristics, pathophysiology, disease manifestations of colorectal cancer. Contemporary issues in colorectal cancer: a nursing perspective 2001, 53-65. Jones and Bartlett, Sudbury, MA. D.T. Berg (Ed.).
14. Levine J.S., Ahnen D.J. Adenomatous polyps of the colon. N Engl J Med 2006, 355:2551-2557.
15. Kim D.H., Pickhardt P.J., Taylor A.J., et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007, 357:1403-1412.
16. Rudy D.R., Zdon M.J. Update on colorectal cancer. Am Fam Phys 2000, 61:1759-1769.
17. Davies R.J., Miller R., Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005, 5:199-209.
18. Soetikno R.M., Kaltenbach T., Rouse R.V., et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008, 299:1027-1035.
19. Walsh J.M., Terdiman J.P. Colorectal cancer screening: scientific review. JAMA 2003, 289:1288-1296.
20. Levin B., Lieberman D., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58:30-60.
21. Imperiale T.F., Glowinski E.A., Lin-Cooper C., et al. Fiveyear risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008, 359:1218-1224.
22. Johnson C.D., Chen M.M., Toledano A.Y., et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008, 359:1207-1217.
23. Quinntero E., Castells A., Bujanda L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012, 366:697-706.
24. Rastogi A., Bansal A., Rao D.S., et al. Higher adenoma detection rates with cap-assisted colonoscopy. Gut 2012, 61:402-408.
25. Qasseem A., Denberg T.D., Hopkins R.H., et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012, 156:378-386.
26. Cancer Facts and Figures 2012 2012, American Cancer Society, American Cancer Society, Atlanta, GA.
27. Use of colorectal cancer tests-United States, 2002, 2004, and 2006. MMWR Morbid Mortal Wkly Rep 2008, 57:253-258. Center for Disease Control.
28. Parikh-Patel A., Bates J.H., Campleman S. Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer 2006, 107(suppl 5):1189-1195.
29. Robbins A.S., Siegel R.L., Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985-2008. J Clin Oncol 2012, 30:401-405.
30. Paskett E.D. Cancer health disparities: moving from why they occur to how they can be prevented. J Clin Oncol 2012, 30:354-356.
31. Emmons K.M., Lobb R., Puleo E., et al. Colorectal cancer screening: Prevalence among low-income groups with health insurance. Health Aff (Millwood) 2009, 28:169-177.
32. Selzner M., Hany T.F., Wildbrett P., et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 2004, 240:1027-1036.
33. National Comprehensive Cancer Network Clinical Practice Guidelines: Colon cancer v.3.2012. Available at: (accessed March 13, 2012). http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
34. National Comprehensive Cancer Network Clinical-Practice Guidelines: Rectal cancer v.3.2012. Available at: pdf (accessed March 13, 2012). http://www.nccn.org/professionals/physician_gls/PDF/rectal.
35. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009. Bethesda, MD; National Cancer Institute. Available at: , based on November 2011 SEER data submission, posted to the SEER Web site, 2012. (accessed August 5, 2012). http://seer.cancer.gov/csr/1975_2009_pops09/.
36. Ryan D.P., Compton C.C., Mayer R.J. Carcinoma of the anal canal. N Engl J Med 2000, 342:792-800.
37. Palefsky J.M., Holly E.A., Efird J.T., et al. Anal intraepithelial neoplasia in the HAART era among HIV-positive men who have sex with men. AIDS 2005, 19:1407-1414.
38. Recommendations on the use of quadrivalent human papillomavirus vaccine in males- Advisory committee on immunization practices (ACIP), 2011. MMWR Morbid Mortal Wkly Rep 2011, 60:1705-1708. Centers for Disease Control (CDC).
39. US Food and Drug Administration. FDA News Release Gardasil approved to prevent anal cancer. 12.22.10. Available at: (accessed March 13, 2012). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm.
40. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadravelent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
41. Kreimer A.R., Gonzalez P., Katki H.A., et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine trial. Lancet Oncol 2011, 12:862-870.
42. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
43. Panagiotis A., Konstantinopoulos H.P., Schlecht B.B., et al. HIV-associated anal squamous cell cancer: an otherwise preventable disease. J Clin Oncol 2006, 24:4516-4517.
44. Wexler A., Berson A.M., Goldstone S.E., et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: Outcome in the era of highly acrive antiretroviral therapy. Dis Colon Rectum 2008, 51:73-81.
45. Salama J.K., Mell L.K., Schomas D.A., et al. Concurrent chemotherapy and intensity-modulted radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 2007, 25:4581-4586.
46. National Comprehensive Cancer Network Clinical Practice Guidelines: Anal cancer. v.2 Available at: (accessed March 13, 2012). http://www.nccn.org/professionals/physician_gls/PDF/anal.pdf.
47. New York State Department of Health AIDS Institute in collaboration with Johns Hopkins University Department of Infectious Disease. HIV Clinical Resource: Human Papillomavirus (HPV). Available at: (accessed August 5, 2012). http://www.hivguidelines.org/wp-content/uploads/human-papillomavirus-hpv-posted-03-12-2012.pdf.
48. Uronis H.E., Bendell J.C. Anal cancer: an overview. Oncologist 2007, 12:524-534.
49. Eliashvili N., Landry J., Matthews R.H. Carcinoma of the anus: strategies in management. Oncologist 2002, 7:188-199.
50. Hoffman R., Welton M.L., Klencke B., et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999, 44:127-131.
51. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Fact Sheet Anal Cancer. Available at: (accessed August 5, 2012). http://seer.cancer.gov/statfacts/html/anus.html.
52. Joseph N.E., Sigurdson E.R., Hanlon A.H., et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003, 10:213-218.
53. Berger A.C., Sigurdson E.R., LeVoyer T., et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005, 23:8706-8712.
54. Johnson P.M., Porter G.A., Ricciardi R., et al. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006, 24:3570-3575.
55. A comparison of laparoscopically assisted an open colectomy for colon cancer. N Engl J Med 2004, 240:2050-2059. Clinical Outcomes of Surgical Therapy Study Group.
56. Benson A.B. Selection of patients with stage II disease for adjuvant therapy. Omm Oncol 2007, 4(suppl3):5-10.
57. Kopetz S., Freitas D., Calabrich A.F.C., et al. Adjuvant chemotherapy for stage II colon cancer. Oncology 2008, 22:260-270.
58. Burdy G., Panis Y., Alves A., et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001, 44:1682-1688.
59. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28:3219-3226.
60. Figueredo A., Charette M.L., Maroun J., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004, 22:3395-3419.
61. Cartwright T.H., Charo C., Lopatin M., et al. Effect of Oncotype DX colon cancer test results on treatment recommendations in patients with stage II colon cancer: preliminary results. J Clin Oncol 2012, 30(suppl 4). (abstr 398).
62. Kelley R.K., Venook A.P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?. Clin Colorectal Cancer 2011, 10:73-80.
63. Sargent D.J., Patiyil S., Yothers G., et al. End points of colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol 2007, 25:4569-4574.
64. Gray R., Barnwell J., Hills R. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007, 370:2020-2029.
65. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
66. de Gramont A., Boni C., Navarro J., et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Proc Am Soc Clin Oncol 2007, 25:165S. (abstr 4007).
67. Baddi L., Benson A. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005, 10:325-331.
68. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies. J Clin Oncol 1999, 17:1349-1355.
69. Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol 2001, 28(suppl 1):14-19.
70. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004, 22:1797-1806.
71. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997, 89:497-505. Liver-Infusion Meta-Analysis Group.
72. Benson A., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
73. Vergo M., Khrizman P., Meropol N.J., et al. Adjuvant chemotherapy for stage II colon cancer: Are we closer to finding the patients who benefit? ASCO Educational Book, pp.123-129 2010, American Society of Clinical Oncology, Alexandria, VA.
74. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
75. Vicuna B., Benson A.B. Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J Natl Compr Cancer Net 2007, 5:927-936.
76. Johnston P.G., Mulligan K., Kay E., et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array. J Clin Oncol 2006, 24(suppl 1). [abstr 3519], 150s.
77. deGramont A, Boni C, Navarro J, et al, Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow up of 4 years [abstr 167]. Hollywood, FL; 2005 ASCO Gastrointestinal Cancers Symposium Proceedings. 2005;1:167.
78. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV {thorn} oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstr 3500]. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. 2005;23(June 1 suppl):246s.
79. Scheithauer W., McKendrick J., Begbie S., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14:1735-1743.
80. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy [abstr 274]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:205.
81. Haller D.G., Tabernero J., Maroun J., et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-1471.
82. Allegra C.J., Yothers G., O'Connell M.J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of the NSABP protocol C-08. J Clin Oncol 2011, 29:11-16.
83. Roche Pharmaceutical Investor Update. Available at: (accessed March 13, 2012). http://www.roche.com/investors/ir_update/inv-update-2010-09-18b.htm.
84. Benson A.B. Adjuvant chemotherapy for stage II and III colorectal cancer. Clin Adv Hematol Oncol 2011, 9:616-618.
85. Beaty K.A., Curley S.A. Metastectomy for combined hepatic and extrahepatic colorectal cancer metastases. Curr Colorec Cancer Rep 2007, 3:89-93.
86. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal (liver) metastases. Ann Surg Oncol 2001, 8:347-353.
87. Vauthey J.N., Pawlik T.M., Abdalla E.K., et al. Is extended hepatectomy for hepatobiliary malignancy justified?. Ann Surg 2004, 239:722-732.
88. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146, and BRAF mutations predict response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
89. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases. J Am Coll Surg 2005, 5:845-853.
90. Michael M, Van Cutsem E, Kretzschmar A, et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat study [abstr 3523]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings. Part I. 2006;24(June 20 suppl):151s.
91. Poston G.J., Adam R., Alberts S., et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005, 23:7125-7134.
92. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases [abstr LBA5]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. Part I. 2007;25(June 20 suppl):2s.
93. Julic C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983 [abstr 241]. Orlando, FL: 2007 ASCO Gastrointestinal Cancers Symposium Proceedings. 2007;1:205.
94. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2010, 11:38-47.
95. National Cancer Institute. Combination chemotherapy before or after surgery in treating patients with colorectal cancer with liver metastases that could be removed by surgery. Available at: (accessed March 16, 2012). http://clinicaltrials.gov/ct2/show/NCT01189227%3fterm%3dNSABP+C-11%26rank%3d1.
96. Fuchs CS, Marshall J, Mitchell EP, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations {thorn}/-celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstr 276]. Orlando, FL: 2007 ASCO Gastrointestinal Cancers Symposium Proceedings. 2007;1:222.
97. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
98. Cassidy J, Clarke S, Diaz-Rubio E, et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 {thorn} bevacizumab or placebo in first-line metastatic colorectal cancer [abstr 341]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:239.
99. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
100. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23:9441-9442.
101. Grothey A., Hedrick E.E., Maas R.D., et al. Response independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107g. J Clin Oncol 2008, 26:183-189.
102. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
103. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
104. Hochster H., Hart L.L., Ramanathan R., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008, 26:3523-3529.
105. DeRoock W., Jonker D.J., DiNicolantonio F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
106. Tejpar S., Bokemeyer C., Celik I., et al. Influence of KRAS G13D mutations on outcome in patients with metatatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2011, 29(suppl). [abstr].
107. Tol J., Nagtegaal I.D., Punt C.J.A. BRAF mutation in colorectal cancer. Letter to the Editor. N Engl J Med 2009, 361:98-99. correction in New Engl J Med 2011;365:869.
108. Samowitz W.S., Sweeney C., Herrick J., et al. Poor survival associated with the BRAFV600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6070.
109. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
110. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
111. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
112. Hecht JR, Mitchell E, Chidiac T, et al. Interim results from PACCE: irinotecan (Iri)/bevacizumab (bev) {thorn}/-panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC) [abstr 279]. Orlando, FL: 2008 ASCO Gastrointestinal Cancers Symposium Proceedings. 2008;1:208.
113. Lievre A., Bachet J.-B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
114. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
115. Grothey A., Sobrero A.F., Siena S., et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012, 30(suppl 4). abstr LBA385.
116. Wang T.-F., Tse V. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights 2012, 6:19-30.
117. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
118. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. J Clin Oncol 2006, 24:394-400.
119. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MCRC): a GERCOR study [abstr 4013]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. Part I. 2007;25(June 20 suppl):166s.
120. Fleshner P.R., Chalasani S., Chang G.J., et al. Practic parameters for anal squamous neoplasms. Dis Colon Rectum 2008, 51:2-9.
121. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
122. Nigro N.D., Vaitkevicius V.K., Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974, 17:354-356.
123. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. JAMA 2008, 299:1914-1921.
124. Meropol N.J., Niedzwiecki D., Shank B., et al. Induction therapy for poor-prognosis anal can carcinoma: a phase II study of the cancer and leukemia Group B (CALGB 9281). J Clin Oncol 2008, 28:3229-3234.
125. James R., Wan S., Glynne-Jones D., et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol 2009, 27(suppl):18s. [abstr LBA4009].
126. Gunderson L.L., Winter K.A., Ajani J.A., et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma. Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol 2011, 29(suppl 4):367.
127. Moureau-Zabotto L., Viret F., Giovaninni M., et al. Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?. J Surg Oncol 2011, 104:66-71.
128. Menkarios C., Azria D., Laliberte B., et al. Optimal organsparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41.
129. Kachnic L.A., Tsai H.K., Coen J.J., et al. Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-insitutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2011, 6:134.
130. Bardia A., Loprinzi C., Grothey A., et al. Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of two widely used prognostic calculators. Semin Oncol 2010, 37:39-46.
131. Gill S., Loprinzi C., Kennecke H., et al. Prognostic Web-based models for stage II and III colon cancer: a population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011, 117:4155-4165.
132. George T.J. KRAS mutational analysis: ready for prime time?. Comm Oncol 2008, 5:435-436.